Added to YB: 2026-04-10
Pitch date: 2026-04-08
ABEO [neutral]
Abeona Therapeutics Inc.
+26.35%
current return
Author Info
No bio for this author
Company Info
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
Market Cap
$340.8M
Pitch Price
$4.82
Price Target
17.00 (+179%)
Dividend
N/A
EV/EBITDA
-2.70
P/E
-5.03
EV/Sales
8.38
Sector
Biotechnology
Category
growth
Abeona Just Made a Quiet Move That Matters
ABEO (update): Added Keith Goldan to board—CFO of SNDX w/ M&A track record across gene therapy cos. Commercial-stage ZEVASKYN for RDEB, $5.8M TTM rev trending to $130M+ by 2026. Beat EPS 3 straight Qs (67%, 5.6%, 35%). HC Wainwright $20 PT ($17 adj) vs $4.91 now = 240%+ upside. Clean balance sheet, 6.93x current ratio, 0.16x D/E. Strategic positioning for M&A or scale-up in hot cell/gene therapy sector.
Read full article (2 min)